Puma Biotechnology Sees Continued Growth and Progress in Q3 2026
Puma Biotechnology, a leading biopharmaceutical company, released its earnings results for the third quarter of 2026, showcasing continued growth and progress across various fronts.
According to Alan Auerbach, Chief Executive Officer, President, and Chairman of the Board of Puma Biotechnology, the company reported total revenue of $55.1 million in Q3 2026, a notable increase from $53.6 million in Q2 2026 and $51.9 million in Q3 2025. This growth can be attributed to strong sales of NERLYNX, with product revenue net reaching $54.1 million in the third quarter of 2026.
NERLYNX sales include both U.S. net sales and product supply revenues to Puma's ex-U.S. partners, highlighting the company's expanding global reach and partnerships. Additionally, royalty revenue, which was slightly below $1 million in Q3 2026 compared to $2.9 million in Q2 2026, demonstrates the value that Puma's intellectual property brings to its sub-licensees.
Puma Biotechnology also reported sales data for NERLYNX, with 2,818 bottles sold in the third quarter of 2026, a slight decrease from 2,929 bottles sold in Q2 2026. However, the company estimates that inventory decreased by 82 bottles in Q3 2026, indicating a managed and controlled sales strategy.
The company's ongoing phase II trials for alisertib in small cell lung cancer and HER2-negative ER-positive breast cancer also show promising progress. These trials, referred to as ALISCA-Lung1, ALISCA-Lung2, and ALISCA-Breast1, demonstrate Puma Biotechnology's commitment to developing innovative treatments for various types of cancer.
Maximo Nougues, Chief Financial Officer, will provide further details on the company's financial statements, highlighting key components of its Q3 2026 performance. Heather Blaber and Roger Storms will also discuss NERLYNX commercial activities and the ongoing phase II trials, respectively.
In conclusion, Puma Biotechnology's Q3 2026 earnings results demonstrate continued growth and progress across various fronts, solidifying the company's position as a leader in the biopharmaceutical industry. With its strong sales of NERLYNX, expanding global reach, and promising phase II trials for alisertib, Puma Biotechnology remains an exciting investment opportunity."
